<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26640">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777815</url>
  </required_header>
  <id_info>
    <org_study_id>PR-610404-100</org_study_id>
    <secondary_id>09/1819</secondary_id>
    <nct_id>NCT01777815</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the NeoChord Device</brief_title>
  <acronym>TACT</acronym>
  <official_title>Safety and Performance Study of the NeoChord Suturing Device in Subjects With Degenerative Mitral Valve Disease; Diagnosed With Severe Mitral Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoChord</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoChord</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and performance of the NeoChord
      DS1000 Artificial Chordae Delivery System in implanting ePTFE sutures(s) as artificial
      neochordae in patients with mitral regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The placement of at least one neochord using the DS1000 System AND a reduction in mitral regurgitation &lt;= 2+ at the time of the procedure AND maintained MR reduction of &lt;= 2+ at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural Safety</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the rate of Major Adverse Events (MAE) defined as a combined endpoint of:  death, MI, reoperation for failed surgical repair, non-elective cardiovascular surgery to treat an adverse event, procedural ventilation &gt; 48 hours, procedure-related transfusion of &gt; 2 units blood product, stroke, renal failure, deep wound infection, new onset of permanent AF, and septicemia, through 30 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Implanting ePTFE sutures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeoChord DS1000 Artificial Chordae Delivery System</intervention_name>
    <arm_group_label>Implanting ePTFE sutures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 and &lt; 80 years

          -  Candidate for surgical mitral valve repair or replacement

          -  Isolated posterior leaflet prolapse

          -  Moderate to severe or severe mitral valve regurgitation that is degenerative in
             nature

        Exclusion Criteria:

          -  Anterior or bi-leaflet prolapse

          -  Functional or ischemic MR

          -  NYHA Class IV

          -  Complex mechanism of MR (leaflet perforation, etc)

          -  Significant tethering of leaflets toward LV apex

          -  Severely calcified mitral valve annulus

          -  Inflammatory valve disease

          -  Severe LV dilation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anno Diegeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz und Gefäß-Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz und Gefäß-Klinik</name>
      <address>
        <city>Bad Neustadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Herz-und Gefäßchirurgie</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista &quot;Molinette&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilniaus Universiteto ligonines Santariskiu</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 25, 2013</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NeoChord</keyword>
  <keyword>DS1000</keyword>
  <keyword>Mitral Valve</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>MR</keyword>
  <keyword>Mitral Valve Repair</keyword>
  <keyword>Mitral Valve Prolapse</keyword>
  <keyword>Artificial Chordae</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
